KTRA

Kintara Therapeutics, Inc.

0.10 USD
+0.00 (+3.28%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Kintara Therapeutics, Inc. stock is down -13.42% since 30 days ago. The next earnings date is May 9, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 11 March’s closed higher than February.

About Kintara Therapeutics, Inc.

Kintara Therapeutics, Inc. focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell Val-083 in China.